# Investment Dossier: BMRN
**Rank: #4 | Composite Score: 7.80/10**

## Executive Summary
- Company: BioMarin Pharmaceutical Inc.
- Price: $58.87
- Market Cap: $11.31B
- Cash: $1250M
- Clinical Stage: commercial
- Active Trials: 7/50

## Score Breakdown

| Component | Score | Weight | Contribution |
|-----------|-------|--------|--------------|
| Stage | 10.0/10 | 30% | 3.00 |
| Cash (capped) | 6.2/10 | 25% | 1.55 |
| Runway | 10.0/10 | 25% | 2.50 |
| Pipeline | 3.7/10 | 20% | 0.75 |
| **Composite** | **7.80/10** | 100% | **7.80** |

## Financial Reality Check
- Cash: $1250M
- Estimated Runway: ~161mo
- Market Cap: $11.31B
- Daily Volume: 3,013,290 shares

## Data Quality
- Overall Coverage: 85%
- Financial Coverage: 75%

## Risk Warnings
- [PASS] No major risk flags identified


---
*Algorithmically generated. Verify all data before investment decisions.*
